AKBA
NASD Akebia Therapeutics, Inc.$0.7902 ↑ +0.0000 (+0.00%) Trading Up from the previous close of $0.7902, $0.0167 below the day’s high of $0.8069
- YTD change
- -50.92%
- vs 20-day SMA
- -12.08%
- vs 200-day SMA
- -34.77%
Price ranges
Price & Performance
-0.68 (-46.24%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 96.1% away from all-time highs of $20.2500
- AKBA is down 51% since the beginning of the year
- AKBA is down 71% over the past 12 months
- AKBA is down 17% over the past 1 month
- 8% of all AKBA investors are betting against AKBA
AKBA reads poor: price sits below both the 20- and 200-day averages, the 12-month move is -71.6%.
- Previous minute
- +$0.0017
- Last hour
- +$0.0005
- Last 5 days
- -8.65%
- vs 8-day SMA
- -8.84%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney diseases. The firm is also involved in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vafseo. The company was founded by Joseph H. Gardner, John M. Rice Jr., Michael E. Pape, Josh P. Fairbank, and Robert A. Shalwitz on February 27, 2007 and is headquartered in Cambridge, MA.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.
